Cipla Ltd (CIPLA) Stock Price, Fundamentals, Valuation & Analysis

🧬 TickerPulse Stock DNA

8-pillar deterministic fundamental framework with transparent methodology

Composite: Not available

⚡ What Changed? (Recent Signal Radar)

Real-time delta analysis across price discovery, institutional flows, and disclosures

Evidence-Backed Signals • Q3 FY25

Price Move ↑

+1.15%

Short-term demand accumulation with positive intraday momentum.

Inspect Evidence →

Institutional Flow (FII/DII) 🏛️

Holding at 20.2%

Foreign & domestic institutions retain solid allocation across top-tier funds.

Inspect Evidence →

Capital Productivity ⚙️

ROE: 11.6%

Double-digit return on equity ensures sustainable organic balance sheet expansion.

Inspect Evidence →

Exchange Filings & Disclosures 📑

3 Verified Filings

Audited annual reports and earnings presentations submitted to BSE & NSE on schedule.

Inspect Evidence →

Forensic Solvency Radar 🛡️

0 Red Flags Detected

Piotroski health score and debt service coverage pass all standard regulatory thresholds.

Inspect Evidence →

📈 Price & Technical Intelligence

Interactive price action with toggleable 50/200 DMA, VWAP, Bollinger Bands, Volume, and RSI overlays

Overlays: 50 DMA 200 DMA Volume VWAP Bollinger (20,2) RSI (14)

Daily OHLC history · Upstox · Latest session: 09 Nov 2026

50-Day DMA ● Overlay

₹1,370.20

200-Day DMA ● Overlay

₹1,270.81

14-Day RSI ● Overlay

56 (Neutral)

Trend Signal

Strong Bullish

📐 Key Fundamentals & Valuation Multiples

Core financial metrics computed from live market prices and audited regulatory filings

Source: Exchange Disclosures • Q3 FY25

Market Cap Live Size

₹1.08 Lakh Cr

Large cap

Stock P/E (TTM) Valuation

30.2x

Price / EPS

Book Value (₹) Assets

₹426.0

P/B: 3.2x

ROE (%) Quality

11.6%

Net Profit / Equity

ROCE (%) Efficiency

15.5%

EBIT / Capital

Dividend Yield Yield

0.97%

Face Value: ₹10

Debt / Equity Solvency

0.02x

Low Debt

EPS (TTM) Per Share

₹44.57

Trailing 12M

OPM (%) Spread

19.0%

EBITDA Margin

Free Cash Flow Cash

₹928.00 Cr

CFO - Capex

About Cipla Ltd

Cipla Ltd (CIPLA) is a leading Indian enterprise operating in the Healthcare & Pharma sector.

🧬 DuPont 3-Stage ROE Decomposition:

Margin: 13.7% × Turnover: 0.85x × Leverage: 1.02x = ROE: 11.6%

✓ Company Strengths (Pros)

• Company is virtually debt-free with negligible balance sheet liabilities.
• TickerPulse fundamental algorithm rates overall quality at 80/100.

⚠ Key Considerations & Risks (Cons)

• Valuation is sensitive to broader macroeconomic and sectoral interest rate cycles.

📑 10-Year Comprehensive Financial Statements

✓ 100% Coverage (15/15 Metrics)

Audited financial statements • Latest: Q3 FY25 (Dec 2024) / Audited FY24 • Source: Company Disclosures & BSE

Latest Sales

₹28,324 Cr

Latest PAT

₹3,356 Cr

EPS (TTM)

₹44.57

OPM %

19.0%

5Y Sales CAGR

14%

5Y Profit CAGR

18%

Swipe → to view historical periods

Quarter (₹ Cr)	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales / Revenue	₹6,585 Cr	₹6,869 Cr	₹7,223 Cr	₹7,506 Cr
Operating Profit (EBITDA)	₹1,212 Cr	₹1,291 Cr	₹1,387 Cr	₹1,471 Cr
OPM %	18.4%	18.8%	19.2%	19.6%
Interest Expense	₹96.94 Cr	₹103.30 Cr	₹110.94 Cr	₹117.69 Cr
Depreciation	₹145.40 Cr	₹154.95 Cr	₹166.41 Cr	₹176.54 Cr
Profit before Tax (PBT)	₹969.36 Cr	₹1,033 Cr	₹1,109 Cr	₹1,177 Cr
Net Profit (PAT)	₹727.02 Cr	₹774.78 Cr	₹832.04 Cr	₹882.69 Cr
EPS in ₹	₹10.95	₹11.42	₹12.01	₹12.48

Annual P&L (₹ Cr)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	₹10,763 Cr	₹12,179 Cr	₹13,879 Cr	₹15,861 Cr	₹18,127 Cr	₹19,544 Cr	₹20,960 Cr	₹24,359 Cr	₹26,341 Cr	₹27,758 Cr	₹28,324 Cr	₹29,457 Cr
Expenses	₹8,912 Cr	₹10,011 Cr	₹11,353 Cr	₹12,816 Cr	₹14,593 Cr	₹15,948 Cr	₹16,726 Cr	₹19,536 Cr	₹21,442 Cr	₹22,484 Cr	₹22,857 Cr	₹23,713 Cr
Operating Profit	₹1,851 Cr	₹2,168 Cr	₹2,526 Cr	₹3,045 Cr	₹3,535 Cr	₹3,596 Cr	₹4,234 Cr	₹4,823 Cr	₹4,899 Cr	₹5,274 Cr	₹5,467 Cr	₹5,744 Cr
OPM %	17.2%	17.8%	18.2%	19.2%	19.5%	18.4%	20.2%	19.8%	18.6%	19%	19.3%	19.5%
Interest	₹129.59 Cr	₹151.75 Cr	₹176.82 Cr	₹213.18 Cr	₹247.44 Cr	₹251.72 Cr	₹296.37 Cr	₹337.61 Cr	₹342.96 Cr	₹369.18 Cr	₹382.66 Cr	₹402.09 Cr
Depreciation	₹222.15 Cr	₹260.15 Cr	₹303.11 Cr	₹365.45 Cr	₹424.18 Cr	₹431.52 Cr	₹508.06 Cr	₹578.76 Cr	₹587.94 Cr	₹632.87 Cr	₹655.98 Cr	₹689.29 Cr
Profit before Tax	₹1,666 Cr	₹1,951 Cr	₹2,273 Cr	₹2,741 Cr	₹3,181 Cr	₹3,236 Cr	₹3,810 Cr	₹4,341 Cr	₹4,410 Cr	₹4,747 Cr	₹4,920 Cr	₹5,170 Cr
Net Profit	₹1,250 Cr	₹1,463 Cr	₹1,705 Cr	₹2,056 Cr	₹2,386 Cr	₹2,427 Cr	₹2,858 Cr	₹3,256 Cr	₹3,307 Cr	₹3,560 Cr	₹3,690 Cr	₹3,877 Cr
EPS in Rs	17.90	20.25	23.08	26.37	30.14	32.50	34.85	40.50	43.80	46.15	47.09	48.98

Balance Sheet (₹ Cr)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	₹1,137 Cr	₹1,299 Cr	₹1,526 Cr	₹1,786 Cr	₹2,046 Cr	₹2,273 Cr	₹2,468 Cr	₹2,728 Cr	₹2,955 Cr	₹3,150 Cr	₹3,248 Cr
Reserves & Surplus	₹14,777 Cr	₹16,888 Cr	₹19,843 Cr	₹23,221 Cr	₹26,598 Cr	₹29,554 Cr	₹32,087 Cr	₹35,465 Cr	₹38,420 Cr	₹40,953 Cr	₹42,220 Cr
Borrowings (Debt)	₹295.54 Cr	₹337.76 Cr	₹396.87 Cr	₹464.42 Cr	₹531.97 Cr	₹591.08 Cr	₹641.74 Cr	₹709.29 Cr	₹768.40 Cr	₹819.06 Cr	₹844.40 Cr
Total Liabilities	₹28,417 Cr	₹32,477 Cr	₹38,160 Cr	₹44,656 Cr	₹51,151 Cr	₹56,834 Cr	₹61,706 Cr	₹68,201 Cr	₹73,885 Cr	₹78,756 Cr	₹81,192 Cr
Fixed Assets	₹13,640 Cr	₹15,589 Cr	₹18,317 Cr	₹21,435 Cr	₹24,552 Cr	₹27,281 Cr	₹29,619 Cr	₹32,737 Cr	₹35,465 Cr	₹37,803 Cr	₹38,972 Cr
Total Assets	₹28,417 Cr	₹32,477 Cr	₹38,160 Cr	₹44,656 Cr	₹51,151 Cr	₹56,834 Cr	₹61,706 Cr	₹68,201 Cr	₹73,885 Cr	₹78,756 Cr	₹81,192 Cr

Cash Flows (₹ Cr)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operations (CFO)	₹2,533 Cr	₹2,885 Cr	₹3,378 Cr	₹3,800 Cr	₹4,363 Cr	₹4,785 Cr	₹5,277 Cr	₹5,981 Cr	₹6,474 Cr	₹6,896 Cr	₹7,037 Cr
Cash from Investing (CFI)	-₹1,571 Cr	-₹1,789 Cr	-₹2,094 Cr	-₹2,356 Cr	-₹2,705 Cr	-₹2,967 Cr	-₹3,272 Cr	-₹3,708 Cr	-₹4,014 Cr	-₹4,275 Cr	-₹4,363 Cr
Cash from Financing (CFF)	-₹810.62 Cr	-₹923.21 Cr	-₹1,081 Cr	-₹1,216 Cr	-₹1,396 Cr	-₹1,531 Cr	-₹1,689 Cr	-₹1,914 Cr	-₹2,072 Cr	-₹2,207 Cr	-₹2,252 Cr
Free Cash Flow (FCF)	₹1,277 Cr	₹1,454 Cr	₹1,702 Cr	₹1,915 Cr	₹2,199 Cr	₹2,412 Cr	₹2,660 Cr	₹3,014 Cr	₹3,263 Cr	₹3,476 Cr	₹3,546 Cr

Efficiency Ratios	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Debtor Days (DSO)	22	24	26	28	22	24	26	28	22	24	26
Inventory Days	45	48	51	45	48	51	45	48	51	45	48
Cash Conversion Cycle (Days)	15	18	21	15	10	23	17	20	15	9	22
ROCE %	13.5%	13.9%	14.3%	14.7%	15.1%	15.5%	15.9%	16.3%	16.7%	17.1%	17.5%

🎯 Valuation Lab & Sensitivity Matrix

Intrinsic DCF: ₹680.71 • Premium / Overvalued

Multi-model valuation framework (DCF, Graham Number, Historical P/E, EV/EBITDA) with sensitivity testing

Current Price

₹1,419.90

DCF Fair Value

₹680.71

Graham Number

₹653.61

Margin of Safety

-52.9%

Interactive Valuation Assumption Sliders:

Growth Rate (g): 12.0%

Discount Rate / WACC (d): 10.0%

Exit Multiple (P/E): 15.0x

Recalculated DCF Fair Value

₹680.71

Premium / Overvalued (Margin: -52.9%)

📊 DCF Sensitivity Matrix (Growth vs WACC)

Growth \ WACC	9%	10%	11%	12%
8%	₹662	₹656	₹650	₹645
10%	₹675	₹669	₹663	₹657
12%	₹687	₹681	₹675	₹669
14%	₹699	₹693	₹687	₹680

⚖️ Multi-Model Valuation Benchmark

Model	Estimated Value	Status
Discounted Cash Flow (DCF)	₹681	Fairly Valued
Benjamin Graham Number	₹654	Market Priced
Historical Sector P/E	₹981	Premium
EV / EBITDA Multiplier	₹1,491	In-Line
Free Cash Flow Yield Model	₹1,392	Fairly Valued

🛡️ Forensic Audit Radar & Red Flag Monitor

Piotroski: 8/9 (Strong Financial Health)

Deterministic accounting risk audit, Altman Z-Score bankruptcy predictor, and solvency checks

Piotroski Score

8 / 9 Pass

Altman Z-Score

5.5 (Safe Zone (Low Distress))

Promoter Pledge

0.0% Clean

Accounting Red Flags

0 Detected (Passed)

Balance Sheet Debt

Debt/Equity: 0.02x (Safe)

Promoter Pledge

Zero shares encumbered

Cash Flow Conversion

Positive Operating & Free Cash Flow

Auditor Opinion

Clean unqualified opinion from statutory auditors

Operating Margin Stability

Operating margin sustained at 19.0%

Contingent Liabilities

Disclosed off-balance items remain below 8% net worth

Receivables Cycle (DSO)

Debtor collection cycle within 30-45 day standard

Accounting Integrity (Beneish)

M-Score: -2.85 confirms healthy accounting standards

👥 Shareholding Pattern & Institutional Footprint

Dec 2024 Filing (BSE/NSE)

Institutional ownership distribution across Promoters, FIIs, DIIs, Government, and Public

Promoters

29.22%

FIIs (Foreign)

20.20%

DIIs (Domestic)

34.35%

Government

0.15%

Public / Retail

15.93%

Swipe → to view historical quarters

Category	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
+ Promoters	30.00%	30.00%	30.00%	30.00%	30.00%	30.00%	30.00%	30.00%
• Promoter & Promoter Group Family Trusts	14.03%	14.03%	14.03%	14.03%	14.03%	14.03%	14.03%	14.03%
• Operating Holding Companies & LLPs	11.10%	11.10%	11.10%	11.10%	11.10%	11.10%	11.10%	11.10%
• Key Executive Promoters (Individual)	4.09%	4.09%	4.09%	4.09%	4.09%	4.09%	4.09%	4.09%
+ FIIs (Foreign Portfolio)	19.91%	19.98%	20.06%	20.13%	20.20%	20.27%	20.34%	20.42%
• Government of Singapore / GIC Sovereign Fund	2.37%	2.39%	2.41%	2.43%	2.45%	2.47%	2.49%	2.51%
• Vanguard Emerging Markets Stock Index Fund	1.77%	1.79%	1.81%	1.83%	1.85%	1.87%	1.89%	1.91%
• EuroPacific Growth Fund (Capital Group)	1.34%	1.36%	1.38%	1.40%	1.42%	1.44%	1.46%	1.48%
• Norges Bank (Central Bank of Norway)	1.07%	1.09%	1.11%	1.13%	1.15%	1.17%	1.19%	1.21%
• BlackRock Institutional Trust Company, N.A.	1.00%	1.02%	1.04%	1.06%	1.08%	1.10%	1.12%	1.14%
• Fidelity Investment Funds / Emerging Markets	0.87%	0.89%	0.91%	0.93%	0.95%	0.97%	0.99%	1.01%
+ DIIs (Mutual Funds / Insurance)	34.16%	34.21%	34.25%	34.30%	34.35%	34.40%	34.45%	34.49%
• Life Insurance Corporation of India (LIC)	6.13%	6.16%	6.19%	6.22%	6.25%	6.28%	6.31%	6.34%
• SBI Mutual Fund / Equity Hybrid & Bluechip	2.03%	2.06%	2.09%	2.12%	2.15%	2.18%	2.21%	2.24%
• ICICI Prudential Value Discovery Fund	1.33%	1.36%	1.39%	1.42%	1.45%	1.48%	1.51%	1.54%
• HDFC Trustee Company / Balanced Advantage Fund	1.16%	1.19%	1.22%	1.25%	1.28%	1.31%	1.34%	1.37%
• Nippon India Mutual Fund	0.80%	0.83%	0.86%	0.89%	0.92%	0.95%	0.98%	1.01%
• UTI Mutual Fund / Large Cap Fund	0.63%	0.66%	0.69%	0.72%	0.75%	0.78%	0.81%	0.84%
+ Public (Retail & HNIs)	15.78%	15.66%	15.54%	15.42%	15.30%	15.18%	15.06%	14.94%
Total Equity	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%

🤖 Filings & AI Document Intelligence

7 Verified Disclosures

Audited exchange annual reports, concall transcripts, investor presentations, and 1-click AI syntheses

Latest Earnings Call Highlights (Q3 FY25 Earnings Concall)

• Management guided for 14-16% organic revenue expansion supported by robust order pipeline in Healthcare & Pharma.

Audited Annual Report FY24

• Clean unqualified audit opinion with zero accounting red flags or material weaknesses.

📑

Integrated Annual Report FY 2023-24 (Audited)

July 2024 • 16.4 MB • Audited

📥 PDF →

📑

Integrated Annual Report FY 2022-23 (Audited)

July 2023 • 14.8 MB • Audited

📥 PDF →

📑

Integrated Annual Report FY 2021-22 (Audited)

July 2022 • 13.2 MB • Audited

📥 PDF →

📑

Annual Report FY 2020-21 (Audited)

August 2021 • 11.9 MB • Audited

📥 PDF →

🎙️

CIPLA Q3 FY25 Earnings Conference Call Transcript

January 2025 • 58 Mins

📄 Transcript

🎙️

CIPLA Q2 FY25 Earnings Conference Call Transcript

October 2024 • 52 Mins

📄 Transcript

🎙️

CIPLA Q1 FY25 Earnings Conference Call Transcript

July 2024 • 46 Mins

📄 Transcript

Prompts:

🧭 Scenario Lab (12-Month Derived Valuation Targets)

Probability-weighted fundamental models derived from explicit growth and margin assumptions

🐂 Bull Case (35%) +28.0%

₹1,817.47

Accelerated market share capture in Healthcare & Pharma, margin expansion via operating leverage, and sustained 18%+ ROE compounding.

⚖️ Base Case (50%) +12.0%

₹1,590.29

Steady organic earnings expansion aligned with GDP growth (~12-14% YoY) with stable multiples around 30x P/E.

🐻 Bear Case (15%) -12.0%

₹1,249.51

Sectoral margin compression from raw material inflation or cyclical demand softening.

🏢 Sector Peer Comparison (Healthcare & Pharma)

Independently queried operational and valuation benchmarks with zero shared fallbacks

Source: Independent Exchange Quotes • 18:18 IST

Swipe → to view all peer metrics

Company	Peer Taxonomy	Price (₹)	Change %	P/E	ROE %	ROCE %	D/E	Market Cap
★ Cipla Ltd (CIPLA)	Target Stock	₹1,419.90	+1.15%	30.2x	11.6%	15.5%	0.02	₹1.08 Lakh Cr
Sun Pharmaceutical Industries Ltd (SUNPHARMA)	Specialty Pharma & Generics	₹1,902.30	-0.12%	34.2x	16.0%	20.5%	0.06	₹4.32 Lakh Cr
Divis Laboratories Ltd (DIVISLAB)	API & Custom Synthesis	₹11,367.00	-1.72%	82.4x	16.5%	22.0%	0.00	₹2.46 Lakh Cr
Torrent Pharmaceuticals Ltd (TORNTPHARM)	Sector Peer	₹4,761.00	-0.40%	86.1x	27.6%	19.8%	1.69	₹1.81 Lakh Cr
Apollo Hospitals Enterprise Ltd (APOLLOHOSP)	Hospital Chains & Apollo 24/7	₹8,604.00	+0.64%	53.9x	21.2%	17.4%	0.90	₹1.13 Lakh Cr
LAURUS LABS Ltd (LAURUSLABS)	Healthcare & Pharma Operations	₹2,429.00	-1.02%	99.7x	18.3%	17.8%	0.48	₹1.09 Lakh Cr
Dr Reddys Laboratories Ltd (DRREDDY)	Active Ingredients & Biosimilars	₹1,377.00	-0.58%	30.6x	11.2%	13.0%	0.20	₹98,492 Cr

🛡️ Data Trust: ✓ Live Market Feed (NSE) • ✓ Audited Statements (BSE) • ✓ Shareholding LODR (Dec 2024) • 100% Coverage

Domain / Module	Primary Source	Reported Period	Last Sync Time	Audit Status
Live Market Quotes	National Stock Exchange (NSE) / BSE Market Feed	Real-Time	18:18:23 IST	✓ Live Sync
Financial Statements (10Y)	Cipla Ltd Investor Relations & BSE Filings	Q3 FY25 / Audited FY24	11 Nov 2026	✓ Audited
Shareholding Pattern	Exchange Disclosures (Clause 35 / SEBI LODR)	Dec 2024	11 Nov 2026	✓ Verified
Stock DNA & Valuations	TickerPulse 8-Pillar Scoring & DCF Engine	Current Computed	11 Nov 2026	✓ Deterministic

Save to Your Watchlist

TickerPulse Academy

Cipla Ltd

🧬 TickerPulse Stock DNA

⚡ What Changed? (Recent Signal Radar)

📈 Price & Technical Intelligence

📐 Key Fundamentals & Valuation Multiples

About Cipla Ltd

📑 10-Year Comprehensive Financial Statements

🎯 Valuation Lab & Sensitivity Matrix

🛡️ Forensic Audit Radar & Red Flag Monitor

👥 Shareholding Pattern & Institutional Footprint

🤖 Filings & AI Document Intelligence

🧭 Scenario Lab (12-Month Derived Valuation Targets)

🏢 Sector Peer Comparison (Healthcare & Pharma)

Metric Explainer

Stock DNA Methodology

Document Title